The TAM Subfamily of Receptor Tyrosine Kinases: The Early Years

Int J Mol Sci. 2024 Mar 16;25(6):3369. doi: 10.3390/ijms25063369.

Abstract

The TAMs are a subfamily of receptor tyrosine kinases (RTKs) comprised of three members, Tyro3, Axl and Mer. Evidence in support of the existence of this subfamily emerged from a screen for novel RTKs performed in the laboratory of Dr. Greg Lemke in 1991. A PCR-based approach to selectively amplify tyrosine kinase-specific genes yielded 27 different tyrosine kinase genes, of which 13 were novel (the "Tyros"). Of these, Tyro3, 7 and 12 were more closely related to each other than to any other kinases and it was proposed that they constituted a novel subfamily of RTKs. Additional support for this hypothesis required determining the complete sequences for these receptor tyrosine kinases. By the end of 1991, full-length sequences for Tyro7 (Axl) revealed a unique extracellular domain organization that included two immunoglobulin-like domains and two fibronectin type III repeats. In 1994, the complete sequences for Tyro12 (Mer) and Tyro3 were shown to have an extracellular region domain structure similar to that of Axl. In 1995, Gas6 and Pros1 were reported as ligands for Tyro3 and Axl, setting the stage for functional studies. The Lemke lab and its many trainees have since played leading roles in elucidating the physiological relevance of the TAMs.

Keywords: Axl; Gas6; Mer; MerTK; TAM; Tyro3; protein S; tyrosine kinase.

Publication types

  • Review

MeSH terms

  • Axl Receptor Tyrosine Kinase*
  • Proto-Oncogene Proteins* / genetics
  • Receptor Protein-Tyrosine Kinases / chemistry
  • Receptor Protein-Tyrosine Kinases / genetics
  • Tamoxifen
  • Tyrosine
  • c-Mer Tyrosine Kinase / genetics

Substances

  • Axl Receptor Tyrosine Kinase
  • c-Mer Tyrosine Kinase
  • Proto-Oncogene Proteins
  • Receptor Protein-Tyrosine Kinases
  • Tamoxifen
  • Tyrosine

Grants and funding

This research was supported by an Indiana University award to Anne L. Prieto and by a major grant from the Lilly Endowment, Inc., Indianapolis, IN to Cary Lai.